Interim results of a phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI) Meeting Abstract
| Authors: | Lang, J.; Tagawa, S. T.; Slovin, S.; Emamekhoo, H.; Rathkopf, D.; Abida, W.; Autio, K.; Xiao, H.; Molina, A. M.; Eickhoff, J.; Sperger, J. M.; Dehm, S.; Nanus, D. M.; Kyriakopoulos, C. E. |
| Abstract Title: | Interim results of a phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI) |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S1188 |
| Language: | English |
| ACCESSION: | WOS:000866211601663 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.annonc.2022.07.1892 |
| Notes: | Meeting Abstract: 1406P -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
